Show simple item record

dc.contributor.authorPerkovic, V
dc.contributor.authorNeal, B
dc.date.accessioned2019-12-18T00:01:33Z
dc.date.available2019-12-18T00:01:33Z
dc.date.issued2012-12-27
dc.identifier.citationPerkovic V, Neal B. Trials in Kidney Disease — Time to EVOLVE. New England Journal of Medicine. 2012;367(26):2541-2542. doi:10.1056/nejme1212368en_AU
dc.identifier.urihttps://hdl.handle.net/2123/21544
dc.description.abstractPatients with kidney disease face a substantially increased risk of cardiovascular events and death — one in five patients who are undergoing dialysis die each year in the United States. Elevated parathyroid hormone levels are almost universal in persons with advanced kidney failure and have been associated with these risks. Cinacalcet is an oral calcimimetic agent approved by the Food and Drug Administration (FDA) in 2004 for the treatment of secondary hyperparathyroidism in patients with dialysis-dependent kidney failure. Early reports supported the possibility that cinacalcet conferred cardiovascular protection and reduced fracture risk, although the statistical power of these studies . . .en_AU
dc.language.isoen_AUen_AU
dc.publisherMassachusetts Medical Societyen_AU
dc.relationNHMRC GNT0571281, NHMRC GNT1003111en_AU
dc.rightsFrom The New England Journal of Medicine, V Perkovic, B Neal, Trials in Kidney Disease — Time to EVOLVE, 367(26):2541-2542. Copyright © (2019) Massachusetts Medical Society. Reprinted with permission.en_AU
dc.titleTrials in Kidney Disease — Time to EVOLVEen_AU
dc.typeArticleen_AU
dc.identifier.doi10.1056/NEJMe1212368
dc.type.pubtypePublisher versionen_AU


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record